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Objectives. We tested the hypothesis that, in patients with
stable heart failure, measuring big endothelin-1 (ET-1) plasma
level at rest predicts short-term prognosis better than peak oxygen
consumption (VO2max) at exercise.
Background. Cardiopulmonary exercise testing and evaluation
of neurohumoral plasma factors are established tools to estimate
survival in patients with heart failure. No data, however, exist
comparing the prognostic value of both marker categories simul-
taneously.
Methods. Two hundred twenty-six heart failure patients were
studied in regard to a combined end point of death and prioriti-
zation for urgent cardiac transplantation within 1 year follow-up.
Results. During the study period 149 patients were without
cardiac events (group A), 69 patients died or were urgently
transplanted (group B) and 8 patients were alive after a nonur-
gent heart transplant operation. Norepinephrine (p < 0.0001),
atrial natriuretic peptide (p < 0.001), big endothelin plasma
levels (p < 0.0001 as well as workload, VO2max and achieved
percentage of predicted peak oxygen consumption (pVo2max) (all
p < 0.0001) differed significantly between groups A and B. In
multivariate stepwise regression analysis, however, only big ET-1
plasma concentration (32 5 74.4, p < 0.0001), New York Heart
Association function class (32 5 33.9, p < 0.0001), maximal
workload (32 5 7.2, p < 0.01, and plasma atrial natriuretic
peptide (ANP) concentration (32 5 4.6, p < 0.05) were indepen-
dently related to outcome. Peak oxygen consumption or pVO2max
did not reach statistical significance in this model. Event-free
survival rates were significantly lower in patients with a big ET-1
level of 4.3 fmol/ml or more than with lower big ET-1 levels (p <
0.0001).
Conclusion. We conclude that in patients with chronic heart
failure who are stable on oral therapy measuring big ET-1 and
ANP plasma levels may be a valuable noninvasive adjunct to
improve the prognostic accuracy of detecting high risk patients
compared with exercise testing alone.
(J Am Coll Cardiol 1998;32:1695–700)
©1998 by the American College of Cardiology
As prevalence of heart failure is steadily increasing there is an
imminent need for prognostic markers in the decision process
of heart transplantation (HTx) candidates. Earlier studies
focused specifically on two factor categories, cardiopulmonary
exercise testing (1–3) and degree of neurohumoral activation
at rest (2,4,5). Of the former, in predicting cardiac events such
as death and deterioration to urgent state, percent achieved of
predicted peak oxygen consumption (pVO2max) was superior
to the previously used absolute peak oxygen consumption
(VO2max) (3). This method needs an expensive equipment and
depends on patient cooperation, however. So it is tempting to
use neurohumoral plasma constituents instead, which can be
easily obtained via single venous blood samples.
Though secreted abluminally from vascular endothelial
cells, plasma concentration of endothelin-1 (ET-1), a potent
vasoconstrictive and prolific peptide (6,7), is increased in heart
failure (8–10). Importantly, in proportion to the symptomatic
severity of the syndrome the prohormone big ET-1 is also
elevated (11). In contrast to other neurohormones, both
mature ET-1 and the propeptide big ET-1 correlate closely
with abnormalities in the pulmonary circuit (8,11,12). Plasma
levels of mature ET-1 predicted mortality in heart failure over
a wide range of disease severity (13,14). When tested in
patients with advanced left ventricular dysfunction (left ven-
tricular ejection fraction, LVEF, 20% and less) circulating big
ET-1 levels were also of prognostic significance (15,16). Thus,
depending on the degree of heart failure, concentrations of
ET-1 or big ET-1 in plasma can be useful to estimate survival
and to guide further therapy in such patients.
Because ET-1 is released by the endothelium of the periph-
eral vasculature a role of this local vasoactive substance in the
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exercise limitation of heart failure is likely. Such a relationship
was recently confirmed in a small study showing that plasma
ET-1 levels during exercise correlated inversely with VO2max
(17).
The objective of the present study was to determine the
relative prognostic importance of circulating big ET-1 levels
among other neurohormonal factors at rest compared with
variables derived from cardiopulmonary exercise testing to
enhance the risk stratification of heart failure patients who are
stable on a background therapy of digitalis, diuretics and
angiotensin converting enzyme (ACE) inhibitors.
Patients and Methods
Two hundred twenty-six patients (199 men, 27 women) who
were managed in our heart failure program between 1992 and
1996 were evaluated. All data were obtained within the same
day, except for LVEF, which was measured within 2 months
prior to entrance. All patients received background therapy
consisting of digitalis (digitoxin 0.07 mg/day) diuretics and
ACE inhibitors for at least 3 months. There were no changes in
the therapeutic approach between 1992 and 1996. Except for a
flexible diuretic regimen adjusted to daily weight and symp-
toms, the oral medication was held constant in all patients.
Each patient was followed for 12 months after enrollment,
when the patients were stratified on the basis of clinical
outcome (death, urgent Htx, nonurgent HTx, living without
HTx). When patients died, the cause of death was obtained
from the hospital chart or from interviews with relatives.
Cardiac deaths within 24 hours of acute symptoms heralded by
abrupt loss of consciousness were considered “sudden,”
whereas those resulting from deterioration of congestive symp-
toms were classified as “progressive heart failure.” In case of
rapidly worsening heart failure patients were given higher
priority according to the urgent request mode of Eurotrans-
plant. Such patients received IV bridging support until surgery.
Grade of listing for HTx was performed by a team of physicians
at the thoracic surgery unit who were unaware of plasma big
ET-1 and VO2max levels, however. Accordingly, stable listed
HTx candidates were transplanted according to their original
ranking on the list.
Study groups. Group A (n 5 149) comprised patients who
survived 1 year in stable condition. No patient in this group
required bridging support or underwent HTx during the ob-
servation period (event-free survival).
Group B (n 5 69) consisted of patients who died and those
who were transplanted under priority status according to the
urgent request mode of Eurotransplant.
Group C (n 5 8) consisted of patients who were trans-
planted according to the nonurgent request mode. Such pa-
tients were excluded from further analysis, because in these
patients HTx did not reflect rapid deterioration of heart
failure.
Measurements. The LVEF was determined by radionu-
clide ventriculography with an Elscint system (Apex 415
gamma camera, Israel) using a standard gated equilibrium
blood pole technique (18). All patients underwent an upright
bicycle test with gas-exchange analysis. Expired gas was ana-
lyzed with a commercially available Sensormedics 2900 meta-
bolic measurement cart that was calibrated before each test.
Both the mixing chamber (187 patients) and the breath-by-
breath method (39 patients) were used. A 12-lead electrocar-
diogram (ECG) was monitored continuously and blood pres-
sure was measured at rest and during exercise in 2-min
intervals. After warming up, an increment workload rate of 25
W was selected. Workload was increased every 2 min until
volitional fatigue, dyspnea, leg pain or a drop in blood pressure
occurred. The following parameters were obtained: oxygen
consumption at maximal exercise (VO2max), percentage of
age- and gender-adjusted predicted VO2max (pVO2max), as
calculated according to Wasserman’s equation (19), workload,
carbon dioxide production (VCO2) under maximal exercise,
ventilation (VE) and VE/VCO2.
Blood sampling procedures and hormonal assays. Venous
blood samples were obtained after at least 30 min of rest from
an indwelling catheter to determine baseline levels of big ET-1,
norepinephrine, atrial natriuretic peptide (ANP), and aldoste-
rone. Test tubes were placed on ice and centrifuged immedi-
ately. Plasma samples were stored at 270°C until analysis. Big
ET-1 was measured as immunoreactive big ET-1 by an
extraction-based radioimmunoassay (Biomedica, Vienna, Aus-
tria), as described in detail elsewhere (20). Normal range: 0.8
to 1.8 fmol/ml. Plasma norepinephrine (pg/ml) was measured
by high pressure liquid chromatography. Normal range: 100–
300 pg/ml. The ANP (pg/ml) was measured by a commercial
radioimmunoassay purchased from Eiken Chemical (Tokyo,
Japan). Normal range: 20–65 pg/ml. Plasma aldosterone (pg/
ml) was measured by a commercial radioimmunoassay pur-
chased from Sorin, Biomedica (Saluggia, Italy). Sensitivity:
15 pg/ml. Specificity: 100% for aldosterone and 4.2% for 3
b-5-tetrahydro-aldosterone. Normal range: 35–300 pg/ml.
Statistical analysis. Continuous variables were expressed
as mean value 6 SD. For comparison of groups, the Student t
test was used for analysis of continuous variables and Fisher’s
exact test was used to compare categorical data. A stepwise
proportional hazards regression Cox model was used to deter-
mine the independent predictors of death or HTx under
priority status. A p value of ,0.05 was used as an entry and exit
criterion of the model. Continuous rather than dichotomized
Abbreviations and Acronyms
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variables were used. The falling variables in the model were as
follows: LVEF, New York Heart Association (NYHA)-class,
daily furosemide dosage, big ET-1, ANP, norepinephrine,
VO2max, percent predicted VO2max (pVO2max), ventilation,
VCO2, VE/VCO2 and workload. The Kaplan-Meier survival
analysis was used to compare outcome according to a cutpoint
of 4.3 fmol/ml. All statistical analyses were performed using
SAS (SAS Institute, Cary, NC). A p value of ,0.05 was
regarded as statistically significant.
Results
Patients. A total of 149 patients were 1-year-survivors
(group A) and 32 patients died. Of those, 14 died of progres-
sive heart failure, 16 died suddenly, 1 died of pneumonia and
1 patient died following acute myocardial infarction. HTx was
performed in 45 patients, 37 of these under priority status.
Thus, 69 patients were defined as group B. Nonurgent HTx
(group C, 8 patients) was excluded. All patients received
therapy with similar doses of ACE inhibitors in addition to
digitalis and diuretics, the dose of which was slightly lower in
group A than in group B. Also, distribution of NYHA-score
and LVEF differed between the groups, with slightly higher
values in group A compared to B. Patient characteristics by
study group are given in Table 1.
Univariate analysis. Maximal workload, VO2max as well as
achieved percentage of predicted VO2max were all markedly
higher in group A than in group B. The anaerobic threshold, as
determined in 103 patients in group A and in 71 patients in
group B, was also higher. Moreover, ventilation (VE) under
maximal exercise was also more pronounced in group A,
whereas VCO2 was suppressed in group B, resulting in a
different VE/VCO2 slope between the groups (Table 2). Nor-
epinephrine, ANP and big ET-1 were increased above normal
in both groups, however, with greater elevations in group B
compared to group A (Fig. 1).
Multivariate analysis. A proportional hazards regression
model was built with all variables that were found to differ
significantly in univariate analysis (NYHA-class, daily furo-
semide dosage, LVEF, workload, VO2max, pVO2max, VCO2,
VE, and VE/VCO2, plasma norepinephrine, ANP and big
ET-1). Of these 12 variables, the following provided indepen-
dent prognostic information: 1) big ET-1 (32 5 74.4, p ,
0.0001); 2) NYHA-class (32 5 33.9 p , 0.0001); 3) maximal
workload (32 5 7.2 p , 0.01); and 4) ANP (32 5 4.6 p ,
0.05).
Kaplan-Meier lifetime analysis. Event-free survival rates
were significantly lower in patients with big ET-1 levels $4.3
fmol/ml than in patients with big ET-1 levels below this
cutpoint (p , 0.0001, Fig. 2).
Discussion
The results of this study again confirm that big ET-1 is a
potent prognostic marker in patients with heart failure. Big
ET-1 plasma concentration predicted cardiac death or HTx
under priority status within the following year. A cutoff value
of 4.3 fmol/ml was useful for the assessment of prognosis
regarding imminent need of urgent measures and for identify-
ing low risk patients who can be safely maintained on oral
medical therapy. These data confirm our previous findings
obtained in a similar patient population, but extends the
prognostic import of big ET-1 by the inclusion of cardiopul-
monary exercise testing (15,16). In addition to big ET-1,
Table 1. Patient Characteristics by Study Group
Group A
(n 5 149)
Group B
(n 5 69)
Group C
(n 5 8)
Age (years) 54 6 10 53 6 11 56 6 7
Gender (male/female) 131/18 62/7 6/2
Idiopath/ischemic CMP 113/36 52/17 7/1
NYHA-I/II/III/IV 31/74/39/5 5/11/19/34**** 1/0/4/3
LVEF (%) 17.3 6 8 14.7 6 6** 13.9 6 8
Furosemide (mg/day) 69 6 60 93 6 71** 90 6 83
Captopril (mg/day) (n) 134 6 50 (42) 124 6 40 (12) 100 (1)
Enalapril (mg/day) 34 6 11 (107) 33 6 11 (57) 31 6 15 (7)
Plasma
Sodium (mmol/liter) 138 6 3.3 139 6 3.2 138 6 2.8
Potassium (mmol/liter) 4.4 6 0.9 4.2 6 0.4 4.4 6 0.3
Creatinine (mg/dl) 1.1 6 0.3 1.01 6 0.3** 1.1 6 0.3
Observation days 365 127 6 104 148 6 129
CMP, cardiomyopathy; NYHA, New York Heart Association; LVEF, left
ventricular ejection fraction. Values are mean 6 SD. **p , 0.01. ****p , 0.0001
vs. group A.
Table 2. Exercise Variables by Study Group
Variable
Group A
(n 5 149)
Group B
(n 5 69)
VO2max (ml/kg/min) 15.6 6 5.3 12 6 4.8****
Percent predicted VO2max (%) 47 6 17 36 6 18****
Workload (w) 93 6 35 62 6 28****
AT (ml/kg/min) 9.3 6 3.2 7.3 6 2.4***
VE (l/min) 43 6 14 38 6 11**
VCO2 (l/min) 1.2 6 0.5 0.9 6 0.4****
VE/VCO2 34 6 13 42 6 18**
VO2max, peak oxygen consumption; AT, anaerobic threshold; VE, ventila-
tion; VCO2, carbon dioxide production. Values are mean 6 SD. ****p , 0.0001.
***p , 0.001. **p , 0.01 vs. group A.
Figure 1. Plasma concentrations of norepinephrine, ANP and big
ET-1 in 149 1-year survivors (black bars) and 69 patients who died or
were transplanted under priority status (empty bars). Values are
mean 6 SD.
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functional capacity (by NYHA-class), functional performance
(by workload) and ANP plasma levels provided additional
prognostic information. Though an established risk factor in
other heart failure populations (1,3,21), VO2max or pVO2max
had no independent prognostic import in this study.
As a speculation, the four categories big ET-1, ANP,
symptoms and maximal workload could differentially represent
typical impaired compartments in heart failure. It is well
recognized that ability to exercise depends on cardiac perfor-
mance, pulmonary function, peripheral muscle mass, blood
flow and metabolism (22–24). All these contributing factors are
adversely affected as heart failure progresses. Interestingly,
impaired metabolism of resting skeletal muscle was reported in
patients who were judged to be in NYHA-class III, when
patients do not perceive symptoms at rest (25). Specifically at
this advanced clinical stage increased ET-1 as well as big ET-1
plasma levels are reported (8–12). By pharmacologic inhibi-
tion, ET-1 was found to contribute to vasoconstriction in the
forearm as well as to total peripheral vascular resistance
(26,27).
Measurement of endothelin in heart failure. Endothelin-1
(ET-1) is a 21-amino-acid peptide with potent vascular, car-
diac, and renal actions (6). As with other peptides with high
biologic activity, ET-1 is rapidly cleared, and in case of
abluminal secretion and paracrine action only a fraction of
mature ET-1 can reach the circulation. In patients with heart
failure circulating levels of ET-1 are increased, reflecting
symptoms according to NYHA-class and providing prognostic
information for a wide range of disease severity (8–14). It was
reported, however, that elevation of “immunoreactive ET-1” in
severe heart failure consists mainly of the 39-amino-acid
prohormone big ET-1 (28). It is well known that precursor
elements without biologic activity often circulate in higher
concentration, integrate the secretory activity of endocrine
cells and open an analytic window. We have measured the
circulating concentration of this propetide separately in vari-
ous cardiovascular patient populations and in normals showing
that big ET-1 plasma levels are moderately increased in
hypertension and in mild heart failure, but continue to rise
along with further clinical deterioration of heart failure symp-
toms (11). Moreover, single resting big ET-1 levels were of
prognostic significance when LVEF was as low as 20% and less
and were superior to hemodynamic data and previously estab-
lished neurohumoral plasma variables such as norepinephrine
and ANP (15,16).
Role of increased endothelin levels. The reason of in-
creased ET-1 production in heart failure is certainly multifac-
torial. Apart from the classic physiologic stimuli, such as shear
stress, thrombin, cytokines, norepinephrine, angiotensin II,
and other vasoconstrictors (which are all operative in heart
failure), it was reported that experimental hypoxemia furthers
ET-1 production in humans. Accordingly, raised ET-1 levels as
found in isolated right heart failure correlated inversely with
pulmonary artery oxygen saturation (29). The VE/VCO2 slope
(which signifies the deadspace volume) was also found to be
related to ET-1 plasma levels (17). Thus, oxygen economy may
be an important factor to influence ET-1 metabolism in human
heart failure. Interestingly, in the dog ventricular pacing heart
failure model ET-1 is expressed particularly in the lungs, while
heart and kidney were of minor importance (30). This ac-
corded well with the previous notion that, in heart failure, the
heart is a target rather than the source of increased ET-1 levels
(28). As a speculation, the activation of ET-1 production in
severe chronic heart failure could mirror hidden injury in the
pulmonary vascular bed. This theory is based on the finding
that both mature ET-1 and big ET-1 plasma concentrations
correlate significantly with pulmonary artery pressure (12,15).
The close correlation between ET-1 spillover in the lungs and
pulmonary vascular resistance suggests that this peptide acts
mainly as a local factor rather than as a circulating hormone.
Effect of endothelin receptor blockade. Even more sugges-
tive of a preferential role of ET-1 to narrow the pulmonary
circuit is gained from studies using pharmacologic inhibition of
the endothelin pathway. In a placebo-controlled study of
patients with severe heart failure (LVEF 21% on average) who
were off ACE inhibitors at the time of study, bosentan, a mixed
ETA/ETB receptor antagonist, increased cardiac index and
reduced systemic vascular resistance, suggesting a role of ET-1
in left ventricular afterload (27). However, to an even greater
extent, bosentan reversed the elevated pulmonary vascular
resistance in these patients. Similar effects of bosentan were
seen in a rat heart failure model on top of ACE inhibitors (31).
Of these, rats with the highest ET-1 levels had the greatest
hemodynamic benefit from ET-1 receptor blockade. Structur-
ally, ET-1’s potent prolific effects (7) may induce adverse tissue
growth in heart failure resulting in an increase in the ventric-
ular mass and cavity enlargement of the ventricle. It was
recently reported that in the postinfarct rat model, long-term
treatment with BQ123, a selective ETA-receptor antagonist,
prevented ventricular remodeling and greatly improved sur-
vival in those animals (32). This beneficial effect was accom-
panied by significant amelioration of left ventricular dysfunc-
tion.
Figure 2. Kaplan-Meier analysis showing cumulative rates of event-
free survival in 218 patients with chronic heart failure stratified in two
groups based on big-ET-1 plasma concentration. Patients with plasma
big-ET levels $4.3 fmol/ml differed significantly from patients with
lower big-ET concentrations.
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Effect of current heart failure treatment. In several recent
prospective heart failure trials using ACE inhibitors (33,34) as
well as the b-blocker vasodilator carvedilol (35), changes in
plasma ET-1 levels reflected both the magnitude and the
direction of the response to therapy. Fosinopril in a placebo-
controlled study lowered plasma ET-1 levels to normal with
alterations in plasma ET-1 being the only covariate explaining
the patients’ impression of health status (33). Lisinopril re-
duced plasma ET-1 concentrations as well, albeit only at a high
dose (34). Carvedilol’s beneficial effects were also paralleled by
significant falls in ET-1, and the change in ET-1 after treat-
ment was an independent noninvasive predictor of functional
and hemodynamic responses to therapy in these patients (35).
We have also pursued this question by examining the reaction
of circulating big ET-1 in response to enalapril with similar
results. In treatment responders, big ET-1 levels fell within 6
months, whereas in patients who deteriorated subsequently big
ET-1 levels remained elevated. Moreover, sequential big ET-1
plasma level after 6 months showed a remarkable effect on
prognosis (36). Thus, reduction in ET-1 and big ET-1 plasma
level during therapy can mirror the beneficial effect of phar-
macologic treatment.
Study limitations. A number of noninvasive markers other
than ET-1 provide long-term prognostic information in heart
failure patients. Although norepinephrine (4) and ANP (5)
were among the first to be shown to be associated with a fatal
outcome, both do not clearly predict such. In contrast, other
newer cardiac natriuretic peptides such as N-terminal ANP
and brain natriuretic peptide are also raised in the plasma of
patients with left ventricular dysfunction whether symptomatic
or asymptomatic and have gained popularity as an index of
impending heart failure (37). While ANP is stored in large
concentrations in the atria, brain natriuretic peptide is derived
to much greater extent from the cardiac ventricles. In cardiac
failure, brain natriuretic peptide concentrations increase more
than do ANP concentrations, so that in severe heart failure
plasma brain natriuretic peptide often exceeds plasma ANP.
This differential release rate may make brain natriuretic pep-
tide concentrations a more sensitive indicator of left ventricu-
lar dysfunction as ANP concentrations. Our investigation did
not include N-terminal ANP and brain natriuretic peptide
plasma level measurements. Thus, further studies are neces-
sary to validate the prognostic value of ET-1 or big ET-1 in
comparison with these important cardiac hormones.
Clinical implications. The present study demonstrates that
the use of 4.3 fmol/ml big ET-1 plasma levels as a cutoff point
provides short-term prognostic information in heart failure
patients independent of functional capacity. From its objective
and noninvasive character on one side, and its stronger infor-
mative potency on the other, determination of big ET-1 in
plasma at rest appears to be an excellent alternative to
VO2max, or pVO2max at exercise, in particular in HTx candi-
dates. Measurement of plasma big ET-1 levels can further
improve the selection process and prevent adverse outcomes.
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